肺移植治疗肺弥漫性病变的疗效观察(附37例报告)

目的 观察肺移植治疗肺弥漫性病变的临床效果.方法 2002年9月至2009年4月,共对72例患者进行了肺移植,其中肺弥漫性病变患者37例.37例中,男性30例,女性7例,年龄(52.9±13.2)岁;原发病包括特发性肺间质纤维化30例,矽肺4例,肺淋巴管平滑肌瘤病2例,弥漫性泛细支气管炎1例.术前和术后常规监测肺功能,采用心脏超声检测肺动脉收缩压,并通过动脉血气分析计算氧合指数(氧分压/吸入氧浓度).观察和比较受者移植前后各项肺功能检测指标的变化.结果 术后1周,受者的肺动脉收缩压较术前有明显下降,从(54.30±17.41)mm Hg(1 mm Hg=0.133 kPa)降至(41.52±9.36)mm Hg(P＜0.05),氧合指数明显改善,从185.89±77.25上升至392.12±98.23(P＜0.05).术后1个月时,肺功能较术前明显改善,用力肺活量(FVC)由术前的(1.52±0.71)L上升至(2.26±0.64)L;第1秒用力呼气量(FEVl)由术前的(1.33±0.64)L上升至(1.81±0.57)L;一氧化碳弥散量由术前的(2.87±1.26)L上升至(4.22±2.05)L;各项检测值与术前比较,差异均有统计学意义(P＜0.05).结论 肺移植是治疗肺弥漫性病变的有效方法,可明显提高患者的存活率和生存质量.

Therapeutic effects of lung transplantation for diffuse pulmonary disease

Objective To observe the therapeutic effects of lung transplantation for diffuse pulmonary disease. Methods From September 2002 to April 2009, lung transplantation was performed on 72 cases in our hospital. Thirty-seven cases of these recipients were suffered from diffuse pulmonary disease, including idiopathic pulmonary fibrosis (30/37), pneumosilicosis (4/37), vascular leiomyoma (2/37) ,diffuse panbronchiolitis (1/37),30 males and 7 females with age ranging from 22 to 73 years old (mean 52.9 ± 13.2). All the patients received pulmonary function test and echocardiography (ECHO) to test the pulmonary artery systolic pressure before transplantation and artery blood gas to calculate the oxygenation index (PaO2/FiO2 ). Results The systolic pulmonary artery pressure (Ppa,syst) was monitored by Swan-Gans catheterization one week post-transplant, and decreased significantly from 54. 30 ± 17. 41 to 41.52 ± 9. 36 mm Hg (P＜0. 05). Simultaneously, oxygenation index was improved from 185. 89 ± 77. 25 to 392. 12 ± 98. 23 (P＜0. 05). The pulmonary function was also improved significanzly one month post-operation. The volume in the first second was improved from (1.33 ± 0. 64) to (1.81 ± 0. 57) L, and the diffusion capacity of carbonmonoxide was increased from (2. 87 ± 1.26) to (4. 22 ± 2. 05) L. Conclusion Lung transplantation is feasible and efficient to deal with diffuse pulmonary disease.